Table 3.
SVR (ITT) according to ART (N = 132)
| ART, n (%) | N | SVR |
|---|---|---|
| ABC/3TC/DTG | 48 | 45/48 (93.8) |
| TDF/FTC/RPV | 22 | 21/22 (95.5) |
| TAF/FTC/EVG-c | 13 | 12/13 (92.3) |
| ABC/3TC + RPV | 9 | 9/9 (100) |
| TDF/FTC + DTG | 8 | 8/8 (100) |
| TDF/FTC/EVG-c | 7 | 7/7 (100) |
| ABC/3TC + RAL | 5 | 5/5 (100) |
| TDF/FTC + RAL | 4 | 4/4 (100) |
| DTG/3TC | 4 | 3/4 (75) |
| TAF/FTC/BIC | 1 | 1/1 (100) |
| TAF/FTC/DRV-c | 1 | 1/1 (100) |
| TAF/FTC + DTG | 1 | 1/1 (100) |
| TAF/FTC/RPV | 1 | 1/1 (100) |
| ABC/3TC + NVP | 1 | 1/1 (100) |
| ABC/3TC + DRV-c | 1 | 1/1 (100) |
| TDF/FTC/EFV | 1 | 1/1 (100) |
| DTG/RPV | 1 | 1/1 (100) |
| DRV-c + MVC | 1 | 1/1 (100) |
| DRV-c | 1 | 1/1 (100) |
| No ART | 2 | 2/2 (%) |
There was no statistical difference among ART (P = 0.156). One patient on other combinations showed discontinuation due to adverse events (cirrhotic patient with Child–Pugh score B7 who developed hepatic encephalopathy). ABC, abacavir; 3TC, lamivudine; DTG, dolutegravir; FTC, emtricitabine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; EVG-c, elvitegravir-cobicistat; FTC, emtricitabine; RPV, rilpivirine; RAL, raltegravir; BIC, bictegravir; DRV-c, darunavir-cobicistat; EFV, efavirenz; MVC, maraviroc; NVP: nevirapine.